



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

June 1, 2021

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2021.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company:
Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands
Wyeth LLC, USA
Wyeth Holdings Corporation, USA
John Wyeth & Brother Limited, UK
Warner - Lambert Company, LLC, USA
Parke - Davis & Company, LLC, USA
Pharmacia Corporation, USA
[Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India
Pfizer Innovative Supply Point International BVBA, Belgium (upto 30 November 2020)
Pfizer Service Company BVBA, Belgium
Pfizer Worldwide Services, Ireland
Pfizer Asia Manufacturing PTE, Singapore
Pfizer Healthcare India Private Limited

D. Key managerial personnel

Mr. S. Sridhar - Managing Director
Mr. Milind Patil - Wholetime Director & Chief Financial Officer
Mr. Vivek Dhariwal - Wholetime Director (upto 14 February 2020)
Mr. Samir Kazi - Wholetime Director
Mr. R A Shah - Independent Director
Mr. Pradip Shah - Independent Director
Mr. Uday Khanna - Independent Director
Mr. Sunil Lalbhai - Independent Director
Ms.Meena Ganesh - Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer

F. Companies in which directors are key managerial personnel/member

Crawford Bayley & Co
Healthvista India Private Limited
Medybiz Pharma Private Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions (Continued)**II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:**

No. Nature of transactions	31 March 2021					31 March 2020				
	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Companies in which directors are exercising significant influence	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Companies in which directors are exercising significant influence	Total
1 Service income	-	-	48.39	-	48.39	-	-	55.19	-	55.19
2 Recovery of expenses	11.64	-	0.48	-	12.12	0.54	0.03	0.19	-	0.76
3 Purchase of stock-in-trade	-	-	367.48	-	367.48	-	-	393.41	-	393.41
4 Purchase of raw / bulk materials	-	-	44.19	-	44.19	-	-	115.05	-	115.05
5 Dividend in respect of the year ended 31 March 2020/ 2019	-	965.02	-	-	965.02	-	65.77	-	-	65.77
6 Liability written back	-	-	-	-	-	-	1.42	8.59	-	10.01
7 Asset transfer	-	2.12	-	-	2.12	-	-	-	-	-
8 Liability transfer	-	-	0.16	-	0.16	-	-	-	-	-
9 Compensation for wind down of consumer business	27.50	-	-	-	27.50	-	-	-	-	-
10 Service fee	-	-	-	0.87	0.87	-	-	-	0.45	0.45
No. Nature of transactions	31 March 2021				Total	31 March 2020				
	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total		Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	
11 Outstanding as at the year end – Due from (Refer note 11 and 14)	39.15	0.10	20.14	59.39	0.54	0.09	20.99	21.62		
12 Outstanding as at the year end – Due to(Refer note 20)	2.09	3.87	135.84	141.80	11.18	6.47	271.20	288.85		

Key managerial personnel

No. Nature of transactions	Year ended 31 March 2021	Year ended 31 March 2020
1 Remuneration to key management personnel *	11.32	9.22

* Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions during the year:

	Year ended 31 March 2021	Year ended 31 March 2020
a) Service income		
Pfizer Products India Private Limited	22.84	25.60
Pfizer Worldwide Services	25.55	29.59
b) Recovery of expenses		
Pfizer Products India Private Limited	0.48	0.19
Pfizer Inc., USA	11.64	0.54
c) Purchase of stock in trade		
Pfizer Innovative Supply Point Intl BVBA, Belgium	23.18	66.07
Pfizer Service Company BVBA, Belgium	344.30	327.34
d) Purchase of raw/ bulk materials		
Pfizer Service Company BVBA, Belgium	38.97	111.62
e) Dividend paid		
Pfizer East India B.V.	600.15	40.92
Wyeth LLC, USA	185.38	12.64
f) Remuneration to key management personnel		
S. Sridhar	5.03	4.11
Milind Patil	2.73	2.10
Vivek Dhariwal	-	1.88
Samir Kazi	1.90	0.16

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions (Continued)

	As on 31 March 2021	As on 31 March 2020
g) Outstanding as at the year end due from		
Pfizer Worldwide Services	1.20	5.70
Pfizer Products India Private Limited, India	18.94	15.29
Pfizer Inc	39.15	-
h) Outstanding as at the year end due to		
Pfizer Innovative Supply Point Intl BVBA, Belgium	8.12	15.81
Pfizer Service Company BVBA, Belgium	23.79	152.55
Pfizer Export Company, Ireland	82.38	82.85